APLS240816C55000
- 0.15
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Express News | JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $64
Express News | Apellis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $64 From $72
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Express News | Apellis Pharmaceuticals Inc : UBS Cuts Target Price to $83 From $85
Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Price Target Raised to $74.00/Share From $66.00 by Goldman Sachs
Mizuho Adjusts Apellis Pharmaceuticals' PT to $42 From $40, Keeps Neutral Rating
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Express News | Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Apellis Pharmaceuticals Analyst Ratings
Express News | Apellis Pharmaceuticals Inc : Jefferies Raises Target Price to $82 From $80
Buy Rating Affirmed on Apellis Pharmaceuticals Amid Empaveli's Strong Clinical Outcomes and Market Potential
Express News | Apellis Pharmaceuticals Inc : Baird Raises Target Price to $96 From $86
Apellis Pharmaceuticals Shares Surge After Study Results
Sobi, Apellis' Rare Kidney Disease Drug Reduces Proteinuria in Late-Stage Study
Apellis Stock Jumps as Rare Kidney Disease Therapy Succeeds in Trial
Express News | Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Apellis And Sobi Announce Phase 3 VALIANT Study Results For Pegcetacoplan In Rare Kidney Diseases
Express News | Apellis Pharmaceuticals Inc - to Submit Data for US and EU Regulatory Approval